Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: A randomized controlled trial
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis : A randomized controlled trial. / Gudbergsen, Henrik; Overgaard, Anders; Henriksen, Marius; Wæhrens, Eva Ejlersen; Bliddal, Henning; Christensen, Robin; Nielsen, Sabrina Mai; Boesen, Mikael; Knop, Filip Krag; Astrup, Arne; Rasmussen, Marianne Uggen; Bartholdy, Cecilie; Daugaard, Cecilie Laubjerg; Ellegaard, Karen; Heitmann, Berit Lilienthal; Bartels, Else Marie; Danneskiold-Samsøe, Bente; Kristensen, Lars Erik.
In: American Journal of Clinical Nutrition, Vol. 113, No. 2, 2021, p. 314–323.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis
T2 - A randomized controlled trial
AU - Gudbergsen, Henrik
AU - Overgaard, Anders
AU - Henriksen, Marius
AU - Wæhrens, Eva Ejlersen
AU - Bliddal, Henning
AU - Christensen, Robin
AU - Nielsen, Sabrina Mai
AU - Boesen, Mikael
AU - Knop, Filip Krag
AU - Astrup, Arne
AU - Rasmussen, Marianne Uggen
AU - Bartholdy, Cecilie
AU - Daugaard, Cecilie Laubjerg
AU - Ellegaard, Karen
AU - Heitmann, Berit Lilienthal
AU - Bartels, Else Marie
AU - Danneskiold-Samsøe, Bente
AU - Kristensen, Lars Erik
N1 - © The Author(s) 2021. Published by Oxford University Press on behalf of the American Society for Nutrition.
PY - 2021
Y1 - 2021
N2 - Background: Weight loss is critical for preventing and managing obesity-related diseases. There is a notable lack of valid and reliable means to manage patients with overweight/obesity and knee osteoarthritis (KOA).Objective: To determine the efficacy and safety of liraglutide in a 30 mg/d dosing in patients with overweight/obesity and KOA.Methods: The trial was designed as a randomized controlled trial including patients between the age of 18 and 74 y with KOA and a BMI ≥27 (measured in kg/m2).Patients underwent a pre-random assignment diet intervention (week -8 to 0). At week 0, patients having lost >5% of their body weight were randomly assigned to liraglutide 3 mg/d or placebo for 52 wk. The coprimary outcomes were changes in body weight and the Knee injury and Osteoarthritis Outcome Score (KOOS) pain subscale from week 0 to 52.Results: In total, 168 patients enrolled and 156 were randomly assigned to receive liraglutide or placebo. Patients experienced a significant reduction in body weight and KOOS pain during the pre-random assignment dietary intervention period (week -8 to 0). From week 0 to 52 there was a significant difference in body weight between the liraglutide and placebo group (mean changes: -2.8 and +1.2 kg, respectively; group difference, 3.9 kg; 95% CI: -6.9, -1.0; P = 0.008). There was, however, no group difference in KOOS pain (mean changes: 0.4 and -0.6 points, respectively; group difference, 0.9 points; 95% CI: -3.9, 5.7; P = 0.71). Treatment-emergent adverse events related to the gastrointestinal system were experienced by 50.2% and 39.2% of patients in the liraglutide and placebo groups, respectively.Conclusions: In patients with KOA and overweight/obesity liraglutide added after an 8-wk pre-random assignment diet induced a significant weight loss at >52 wk but did not reduce knee pain compared to placebo. This trial was registered at clinicaltrials.gov as NCT02905864.
AB - Background: Weight loss is critical for preventing and managing obesity-related diseases. There is a notable lack of valid and reliable means to manage patients with overweight/obesity and knee osteoarthritis (KOA).Objective: To determine the efficacy and safety of liraglutide in a 30 mg/d dosing in patients with overweight/obesity and KOA.Methods: The trial was designed as a randomized controlled trial including patients between the age of 18 and 74 y with KOA and a BMI ≥27 (measured in kg/m2).Patients underwent a pre-random assignment diet intervention (week -8 to 0). At week 0, patients having lost >5% of their body weight were randomly assigned to liraglutide 3 mg/d or placebo for 52 wk. The coprimary outcomes were changes in body weight and the Knee injury and Osteoarthritis Outcome Score (KOOS) pain subscale from week 0 to 52.Results: In total, 168 patients enrolled and 156 were randomly assigned to receive liraglutide or placebo. Patients experienced a significant reduction in body weight and KOOS pain during the pre-random assignment dietary intervention period (week -8 to 0). From week 0 to 52 there was a significant difference in body weight between the liraglutide and placebo group (mean changes: -2.8 and +1.2 kg, respectively; group difference, 3.9 kg; 95% CI: -6.9, -1.0; P = 0.008). There was, however, no group difference in KOOS pain (mean changes: 0.4 and -0.6 points, respectively; group difference, 0.9 points; 95% CI: -3.9, 5.7; P = 0.71). Treatment-emergent adverse events related to the gastrointestinal system were experienced by 50.2% and 39.2% of patients in the liraglutide and placebo groups, respectively.Conclusions: In patients with KOA and overweight/obesity liraglutide added after an 8-wk pre-random assignment diet induced a significant weight loss at >52 wk but did not reduce knee pain compared to placebo. This trial was registered at clinicaltrials.gov as NCT02905864.
KW - Faculty of Science
KW - Osteoarthritis
KW - Diet
KW - Obesity
KW - Intervention
KW - Liraglutide
U2 - 10.1093/ajcn/nqaa328
DO - 10.1093/ajcn/nqaa328
M3 - Journal article
C2 - 33471039
VL - 113
SP - 314
EP - 323
JO - American Journal of Clinical Nutrition
JF - American Journal of Clinical Nutrition
SN - 0002-9165
IS - 2
ER -
ID: 255505667